Sentiment-Signal
19,4
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Unternehmen & Branche
| Name | PALISADE BIO, INC. |
|---|---|
| Ticker | PALI |
| CIK | 0001357459 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 329,8 Mio. USD |
| Beta | 1,47 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -16,781,000 | -0.30 | 134,344,000 | 129,380,000 | |
| 2025-09-30 | 10-Q | -2,868,000 | -0.38 | 6,973,000 | 3,212,000 | |
| 2025-06-30 | 10-Q | -2,784,000 | -0.58 | 6,667,000 | 2,620,000 | |
| 2025-03-31 | 10-Q | -2,230,000 | -0.47 | 8,190,000 | 5,331,000 | |
| 2024-12-31 | 10-K | 0 | -14,438,000 | -10.19 | 10,880,000 | 7,492,000 |
| 2024-09-30 | 10-Q | 0 | -3,487,000 | -2.32 | 9,336,000 | 6,608,000 |
| 2024-06-30 | 10-Q | 0 | -4,080,000 | -3.32 | 12,871,000 | 9,949,000 |
| 2024-03-31 | 10-Q | 0 | -3,527,000 | -4.59 | 12,652,000 | 10,064,000 |
| 2023-12-31 | 10-K | 250,000 | -12,300,000 | -27.01 | 14,052,000 | 11,313,000 |
| 2023-09-30 | 10-Q | 0 | -3,596,000 | -7.38 | 17,067,000 | 14,082,000 |
| 2023-06-30 | 10-Q | 0 | -3,393,000 | -7.93 | 18,290,000 | 15,800,000 |
| 2023-03-31 | 10-Q | 250,000 | -2,340,000 | -8.13 | 15,262,000 | 13,747,000 |
| 2022-12-31 | 10-K | 0 | -14,260,000 | -16.53 | 15,763,000 | 12,479,000 |
| 2022-09-30 | 10-Q | 0 | -3,991,000 | -4.10 | 16,266,000 | 12,430,000 |
| 2022-06-30 | 10-Q | 0 | -2,344,000 | -5.77 | 7,806,000 | 4,211,000 |
| 2022-03-31 | 10-Q | 0 | -4,205,000 | -12.96 | 8,350,000 | 4,792,000 |
| 2021-12-31 | 10-K | -26,616,000 | -169.74 | 12,512,000 | 7,365,000 | |
| 2021-09-30 | 10-Q | 8,087,000 | 0.42 | 16,274,000 | 3,920,000 | |
| 2021-06-30 | 10-Q | -31,746,000 | -4.10 | 14,949,000 | -9,444,000 | |
| 2021-03-31 | 10-Q | -4,030,000 | 8,914,923 | -20,063,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.